Previous 10 | Next 10 |
home / stock / cere / cere articles
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between (NASDAQ:CERE) Cer...
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc...
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain add...
Monday, AbbVie Inc (NYSE:ABBV) agreed to acquire Landos Biopharma Inc (NASDAQ:LABP) for $20.42 per share, or approximately $137...
RBC Capital Markets has initiated Biohaven Ltd (NYSE:BHVN), noting optimized development across programs. The analyst highlight...
UBS initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), a biotech firm focused on developing and marketing therapies for ce...
Friday, AbbVie Inc (NYSE:ABBV) reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth...
William Blair has upgraded AbbVie Inc (NYSE:ABBV), noting confidence in the company’s growth outlook over the near and long te...
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...